on Friday said it has opened its new manufacturing plant for generic oral cancer medicines at Kalwe in Mumbai.
Spread across 32,000 sqm, and housing state-of-the-art production technology, the plant is built to cater to export markets. It currently has a workforce of 70 people with plans to increase further to support the expansion of production capacity and capabilities.
Built on a brownfield site, the plant has effluent treatment units installed to support sustainable manufacturing operations.
Novartis said the plant, which marks a new chapter for its Sandoz business will further strengthen the company’s operations in India and play a key role in driving global growth for its generics business.
“Today marks an important milestone for us at Novartis, and particularly for our Sandoz division, a global leader in generic pharmaceuticals and biosimilars. The inauguration of the new production and launch site for Oncology oral solids at Kalwe in India is a step forward in our constant endeavor to pioneer
access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs,” said Sanjay Murdeshwarcountry president,
“Moreover, the launch of this facility will support the government’s ‘Make in India’ vision to find solutions for the evolving needs of patients around
the world,” Murdeshwar added.
Novartis, through its Sandoz division, sells off-patent medicines in areas including oncology, immunology, and anti-infectives.